Results 171 to 180 of about 3,430 (200)
Some of the next articles are maybe not open access.

Phase I trial of the HSP-90 inhibitor PU-H71.

Journal of Clinical Oncology, 2015
2537 Background: PU-H71 (PU) is an HSP-90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU) PET imaging, leading to a surrogate marker of intratumoral pharmacokinetics.
John F. Gerecitano   +19 more
openaire   +1 more source

Hsp90 Inhibitor PU-H71, a Multimodal Inhibitor of Malignancy, Induces Complete Responses in Triple-Negative Breast Cancer Models [PDF]

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2009
Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified targets and targeted therapies, and due to a heterogeneous molecular presentation, treatment guidelines for patients with TNBC include only conventional chemotherapy.
Ana I Robles   +2 more
exaly   +3 more sources

MPEC 2023-H71 : 2019 QT

2023
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

Characterization of Bacillus thuringiensis ser. jordanica (Serotype H71), a Novel Serovariety Isolated in Jordan

Current Microbiology, 2003
The novel strain of Bacillus thuringiensis J112 isolated from a soil sample in Jordan was classified and characterized in terms of toxicity against dipteran and nematode larvae, crystal protein pattern, plasmid profile, and cry gene content. A new name, Bacillus thuringiensis serovariety jordanica (H serotype 71), is proposed for the reference strain ...
Hala, Khyami-Horani   +2 more
openaire   +2 more sources

PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

Molecular and Cellular Biochemistry, 2013
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT ...
Zhuling, Qu   +3 more
openaire   +2 more sources

Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.

Journal of Clinical Oncology, 2010
8141 Background: PU-H71, a novel purine scaffold HSP90 inhibitor, has demonstrated anti-tumor activity in triple-negative breast cancer and Bcl6 dependent B-cell lymphoma preclinical models.
S. Z. Usmani   +3 more
openaire   +1 more source

Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.

Journal of Clinical Oncology, 2013
3101 Background: Heat shock protein (HSP) 90 regulates the disposition and activity of a large number of deregulated proteins in Ewing sarcoma. We have shown pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor developed at MSKCC, in Ewing sarcoma. Unfolded proteins as a result of HSP90 inhibition are degraded via the ubiquitin-proteasome pathway
Srikanth R. Ambati   +8 more
openaire   +1 more source

Abstract 7326: PU-H71 alters metabolism to suppress growth in pancreatic cancer

Cancer Research
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options. Oncogenic KRAS signaling, mainly via the mitogen-activated protein kinase (MAPK) pathway, is the key driver of PDAC. To sustain its growth and resist therapy, PDAC tumors continuously reprogram their metabolic activities.
Chiamaka J. Ezeh   +3 more
openaire   +1 more source

Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma

Blood, 2008
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Although many DLBCLs are responsive to CD20 antibody/chemotherapy regimens, a significant proportion of patients will still die of their disease. It is possible that targeting important lymphomagenic pathways could improve the potency and reduce the ...
Gabriela Chiosis   +4 more
openaire   +1 more source

Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Cancer Research, 2019
Abstract Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP90 is integrated into the epichaperome (Rodina et al. Nature 2016).
K Jhaveri   +16 more
openaire   +1 more source

Home - About - Disclaimer - Privacy